Eli Lilly and Company (NYSE:LLY) Shares Sold by DE Burlo Group Inc.

DE Burlo Group Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 41.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,938 shares of the company’s stock after selling 16,863 shares during the quarter. Eli Lilly and Company comprises 2.5% of DE Burlo Group Inc.’s investment portfolio, making the stock its 17th largest holding. DE Burlo Group Inc.’s holdings in Eli Lilly and Company were worth $18,480,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after buying an additional 60,306 shares during the period. Invst LLC boosted its holdings in shares of Eli Lilly and Company by 3.5% in the third quarter. Invst LLC now owns 5,552 shares of the company’s stock valued at $4,918,000 after acquiring an additional 189 shares in the last quarter. McIlrath & Eck LLC boosted its holdings in shares of Eli Lilly and Company by 3.4% in the third quarter. McIlrath & Eck LLC now owns 481 shares of the company’s stock valued at $426,000 after acquiring an additional 16 shares in the last quarter. Virtu Financial LLC increased its stake in shares of Eli Lilly and Company by 111.7% during the third quarter. Virtu Financial LLC now owns 6,531 shares of the company’s stock worth $5,786,000 after acquiring an additional 3,446 shares during the period. Finally, SOA Wealth Advisors LLC. raised its holdings in Eli Lilly and Company by 2.4% during the third quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company’s stock worth $766,000 after purchasing an additional 20 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday. They set an “overweight” rating and a $975.00 price objective on the stock. Wells Fargo & Company raised their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Citigroup lowered their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Finally, Guggenheim reduced their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,017.00.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $884.94 on Friday. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company’s 50 day simple moving average is $827.69 and its 200 day simple moving average is $818.61. The company has a market capitalization of $839.07 billion, a price-to-earnings ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.